The results of intravitreal bevacizumab monotherapy for treating aggressive posterior retinopathy of prematurity and Type 1 retinopathy of prematurity.

Çömez A., Karaküçük Y., Özmen M. C., Çelemler P., Saygılı O.

Eye (London, England), cilt.35, sa.12, ss.3302-3310, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 35 Sayı: 12
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1038/s41433-021-01413-4
  • Dergi Adı: Eye (London, England)
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, CINAHL, Design & Applied Arts Index, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.3302-3310
  • Gazi Üniversitesi Adresli: Evet

Özet

Objectives This study evaluated the efficacy of intravitreal bevacizumab (IVB) monotherapy for aggressive posterior retinopathy of prematurity (APROP) and Type 1 retinopathy of prematurity (ROP), along with recurrence rates and treatment outcomes for recurrences.